Antibody drug conjugate (ADC)

Clinical research
#Antibody drug conjugate (ADC) #Artificial intelligence (AI) #Cell and gene therapy #Drug development #Drug discovery #mRNA-based vaccines #Roundtable

Roundtable: What will have most impact on drug discovery trends?

Hosted by DDW and supported by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ will be free to attend on June 28 at 8AM PT | 11AM ET | 4PM BST | 5PM CET. Join this free roundtable… Read More

Webinar date:
Sponsored by DNA Script
#News

Medical research
#Antibody drug conjugate (ADC) #Artificial intelligence (AI) #Cell and gene therapy #Drug development #Drug discovery #mRNA-based vaccines #Roundtable

Join our roundtable on drug discovery and development trends

Hosted by DDW and sponsored by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ will be free to attend on June 28 at 8AM PT | 11AM ET | 4PM BST | 5PM CET. Join this free roundtable… Read More

Webinar date:
Sponsored by DNA Script
#News

Drug discovery
#Antibody drug conjugate (ADC) #Artificial intelligence (AI) #Cell and gene therapy #Drug development #Drug discovery #mRNA-based vaccines #Roundtable

Exclusive roundtable on drug discovery and development trends

Hosted by DDW and sponsored by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ will be free to attend on June 28 at 8AM PT | 11AM ET | 4PM BST | 5PM CET. Join this free roundtable… Read More

Webinar date:
Sponsored by DNA Script
#News

Drug discovery
#Antibody drug conjugate (ADC) #Artificial intelligence (AI) #Cell and gene therapy #Drug development #Drug discovery #mRNA-based vaccines

Drug discovery and development trends – what will have most impact?

Hosted by DDW and sponsored by DNA Script, watch this free roundtable on demand to learn about the biggest opportunities for the future of drug discovery and development. Roundtable panellists include Commercial Research Scientist, Dr Mark Treherne, CEO of Elevation Oncology, Joe Ferra, and CEO of BioXcel… Read More

Webinar date:
Sponsored by DNA Script
#Webinars

#Antibodies #Antibody drug conjugate (ADC) #Apexigen #Mergers and acquisitions #Oncology #Pyxis Oncology

Pyxis Oncology to acquire antibody therapeutics company Apexigen

Pyxis Oncology has announced a definitive agreement by which it will acquire Apexigen in an all-stock transaction for an implied value of $0.64 per Apexigen share. For each share of Apexigen, Pyxis Oncology will issue 0.1725 shares of its common stock, par value $0.001 per share, for a total enterprise… Read More

#Business & Investment #News

Adcendo Lab
#Antibodies #Antibody drug conjugate (ADC) #Biotech #Drug development #Seed funding

Financing ensures development of Adcendo’s ADC asset 

Adcendo, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, has completed a successful Series A extension financing round, raising a further €31 million, following the €51 million Series A financing in April 2021. Read More

#News

Antibody drug conjugate
#AI / data analytics / healthtech / informatics #Antibodies #Antibody drug conjugate (ADC) #Big pharma #Drug development #Precision medicine

A personal view on antibody drug development

Oliver Schon, PhD, is VP Research & Development at BiVictriX Therapeutics, a UK-based emerging drug discovery and development company generating a pioneering first-in-class next-generation ADC anti-cancer therapeutics which exhibit superior selectivity towards cancer. Dr Schon is applying his broad expertise from lead discovery to manufacture in order to progress differentiated,… Read More

#Exclusive Content

Medical laboratory
#Antibody drug conjugate (ADC) #Bio-Thera Solutions #Cancer research #Oncology #Phase I trial #Solid tumours

Company launches ADC Phase I trial in solid tumours

Dosing has begun in a Phase I clinical study evaluating BAT8008, an antibody-drug conjugate (ADC) that targets Trop2.   Key objectives of the study are to determine the maximum tolerated dose (MTD), recommended Phase II dose (RP2D), and to evaluate the pharmacokinetics and preliminary efficacy in patients with… Read More

#Cancer Research #News

Breast cancer treatment
#Antibody drug conjugate (ADC) #Breast cancer #Cancer research #FDA #Gilead Sciences #GlobalData #Oncology

ADC potential “standard of care” for some breast cancer patients

The FDA has granted expanded approval for Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy) for patients with HR-positive/HER2-negative metastatic breast cancer who have received hormonal therapy and at least two additional therapies in the metastatic setting.  The drug is expected to become a standard of care for these patients,… Read More

#News #Trending News

Antibody drug conjugate
#Antibodies #Antibody drug conjugate (ADC) #Collaboration #License agreement #Partnership #Precision medicine

Collaboration will combine ADC technology and precision therapeutics

Synaffix and Hummingbird Bioscience have entered into a licensing agreement that it is hoped will enable Hummingbird Bio to develop an antibody drug conjugate (ADC) programme using Synaffix technology.   Under the terms of the agreement, Synaffix will be eligible to receive up to $150 million, including upfront and milestone payments,… Read More

#Business & Investment #News

Detecting antibodies in a lab
#Antibodies #Antibody #Antibody drug conjugate (ADC) #Antibody-based therapeutics #Collaboration #Drug discovery #Market reporting #Partnership

Partnerships and collaborations fuel antibodies market growth

Increasing collaborations and partnerships between market players are expected to contribute to significant growth in the antibodies market between 2022 and 2030, ResearchAndMarkets.com predicts.   In one example from March 2022, Sanofi and Seagen announced an exclusive collaboration agreement to design, develop, and market antibody-drug conjugates (ADCs) for up to three… Read More

#Business & Investment #Market Reports #News

Two scientists working in a research laboratory
#Antibody #Antibody drug conjugate (ADC) #Cancer research #Collaboration #Merck #Mersana Therapeutics #Partnership #Tumours

Research partners hope to develop novel antibody-drug conjugates

Mersana Therapeutics and a subsidiary of Merck have entered a research collaboration to discover novel Immunosynthen antibody-drug conjugates (ADCs) directed against up to two targets.  Under the terms of the agreement, Mersana will develop novel ADC product candidates against up to two targets utilising its Immunosynthen platform to conjugate proprietary… Read More

#Business & Investment #News

#Antibody drug conjugate (ADC) #Diagnostics #Oncology

This week in drug discovery (13-17 June)

News round-up by DDW’s Reece Armstrong for 13-17 June. Partnerships, awards, and new companies are some of the topics of this week’s news round-up. Bachem & Eli Lilly partner on oligonucleotide project Swiss pharmaceutical company Bachem has partnered with Eli Lilly on a seven-year agreement to advance the development of… Read More

#News

#Antibody drug conjugate (ADC) #Investment #Oncology

Spirea raises £2.4m to develop ADC cancer therapies  

A University of Cambridge spin-out has secured £2.4 million of investment to help it develop a pipeline of antibody drug conjugate (ADC) therapies for solid tumours.  Spirea is developing ACD therapeutics for solids tumours with a high unmet need. The company has developed technology that enables more cytotoxic drug to… Read More

#Business & Investment #News